| in neuroblastoma, miR-27b functions as a tumor suppressor by inhibiting the tumor-promoting function of PPARgamma, which triggers an increased inflammatory response | neuroblastoma, |
| miR-23b and miR-27b function as tumor suppressors, targeting several oncogenic genes in clear cell renal cell carcinoma cells | kidney, |
| downregulation of the miR-23b/27b/24-1 cluster was a frequent event in prostate cancer, and these clustered miRNAs functioned as tumor suppressors | prostate, |
| Results showed that miR-23b and miR-27b were frequently reduced in oral squamous cell carcinoma clinical specimens and appeared to act as tumor suppressors through targeting of the MET oncogene in this disease. | oral |
| findings reveal that miR-27b is a tumor suppressor in gastric cancer and a biomarker for improving patients_ survival. | gastric, |
| results demonstrate that miR-23b and miR-27b are primarily oncogenic in MCF7 breast cancer cells and that miR-27b may have tumor suppressive activity under certain circumstances | breast, |
| MiR-27b-3p exerts tumor suppressor effects in esophageal squamous cell carcinoma by targeting Nrf2 | esophageal, |
| Tumor-suppressor miRNA-27b-5p regulates the growth and metastatic behaviors of ovarian carcinoma cells by targeting CXCL1 | ovarian, |